Possible new Avalo Therapeutics shares
AVTXDilution
Known so far: no new shares from the prospectus covers read · shelf room about $17.9M · not yet read: converts.
Shelf room
- Room today about $17.9M
- One third of float $17.9M ($53.7M float, Jun 30, 2025)
- Sold off it, 12 months nothing
How this is worked out
Shelf room about $17.9M on the S-3ASR of Nov 5, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $53.7M public float stated as of Jun 30, 2025, $17.9M, nothing sold off it in the last 12 months. Sources: S-3ASR Nov 5, 2026, effective Nov 5, 2026 · public float, as of Jun 30, 2025.
What could become new Avalo Therapeutics (AVTX) shares: warrants, options and RSUs and an ATM program, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.
Avalo Therapeutics dilution ladder
Every source of new shares on record, from the filings that created it.
53.9M outstanding; up to 87.8M fully diluted, +63%
- Outstandingas of Nov 5, 2026 (424B5 cover) · Prospectus cover, shares outstanding before the offering53.9M
- At-the-market program$200.0M program424B5 Nov 5, 2026 · At-the-market prospectus supplementat $7.07, stated in the filing on Nov 4+28.3M
- +148
- +5.6M
Not stated in the filings we read: convertible notes.
Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.
Financing terms to know
None found in filings since Nov 5, 2026.
Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.
Shares outstanding
57.8M
Mar 2025 to Nov 2026: from 10.7M to 57.8M.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow Avalo Therapeutics
New shelves, offerings, 10-Qs and 10-Ks from AVTX, explained in plain English when they reach EDGAR.
Watch AVTX in the appData on this page was fetched . The filing on SEC.gov is the record.